Physician profile
Ganesh N Pulla
NPI 1679620918
$3,593.09
in general payments reported to CMS, 2019-2025
34 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $31.39 · 2021: $186 · 2022: $340 · 2023: $554 · 2024: $1,991 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,524 · Travel and Lodging: $1,175 · Education: $17.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.33 |
| Travel and Lodging | $1,175.48 |
| Education | $17.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $1,861.33 | 2024 | Venclose Maven Catheter |
| Novo Nordisk INC | $261.34 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $172.59 | 2021-2024 | |
| Amgen INC. | $113.07 | 2019-2024 | Tavneos, Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $85.16 | 2019-2022 | |
| Lilly USA, LLC | $83.29 | 2021-2023 | Mounjaro, Trulicity |
| Nestle Healthcare Nutrition INC. | $71.75 | 2021-2023 | |
| Antares Pharma, INC. | $68.71 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $68.44 | 2022-2023 | Jynarque |
| Opko Pharmaceuticals, LLC | $63.70 | 2019-2023 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $58.42 | 2023-2024 | Acthar, Terlivaz |
| Dexcom, INC. | $57.14 | 2021-2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $53.35 | 2019-2021 | |
| Abbvie INC. | $52.47 | 2022-2023 | |
| Travere Therapeutics, INC. | $47.29 | 2021-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $46.35 | 2021-2024 | Varithena Administration Pack |
| Scilex Pharmaceuticals INC. | $41.19 | 2019 | |
| Calliditas Therapeutics US INC. | $39.95 | 2023 | Tarpeyo |
| Lundbeck LLC | $37.78 | 2019 | |
| Vifor Pharma, INC. | $35.98 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $32.99 | 2023 | |
| Astellas Pharma US INC | $30.28 | 2019-2023 | Veozah |
| Becton, Dickinson and Company | $26.19 | 2024 | Venclose Maven Catheter |
| Ani Pharmaceuticals, INC. | $24.37 | 2023 | Purified Cortrophin Gel |
| Acadia Pharmaceuticals INC | $20.85 | 2019 | |
| Medtronic, INC. | $19.61 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.77 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.44 | 2019 | |
| Mylan Specialty L.P. | $15.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.14 | 2022 | |
| Dermira, INC. | $14.02 | 2020 | |
| Abbott Laboratories | $13.66 | 2023 | Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $13.54 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ganesh Pulla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.